PharmaLogic Holdings
PharmaLogic Holdings is a privately held U.S. radiopharmaceutical CDMO/CMO operating multiple manufacturing facilities that provide CMC, production, and supply chain services for diagnostic and therapeutic radiopharmaceuticals to pharmaceutical sponsors, hospitals, and imaging centers.
- Company typePrivate
- Founded1993
- HeadquartersBoca Raton, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PharmaLogic Holdings does
PharmaLogic Holdings Corp. is a privately held radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) founded in 1993 and headquartered in Boca Raton, Florida. The company delivers end-to-end Chemistry, Manufacturing, and Controls (CMC) and technical capabilities that enable pharmaceutical sponsors to advance diagnostic and therapeutic radiopharmaceutical products from clinical development through commercial launch. Its four core service lines are CDMO Services, CMO Diagnostics (including PET drug manufacturing), CMO Therapeutics (including Actinium-225-based targeted radiotherapeutics for cancer), and Supply Chain & Radiopharmacy distribution.
Operationally, PharmaLogic runs a multi-site U.S. manufacturing network spanning Atlanta, Georgia (a $250 million facility opened in April 2026), Idaho Falls, the Bronx, Cincinnati, Salt Lake City, Los Angeles, and New York, with international capacity added through the 2024 majority acquisition of Norway-based Agilera Pharma. The infrastructure is purpose-built for short-half-life radiopharmaceuticals that require just-in-time production and regional distribution to hospitals and imaging centers. PharmaLogic operates under FDA Part 212 quality standards as a PET drug manufacturer.
The company is sales-led and B2B, serving two primary segments: pharmaceutical sponsors requiring radiopharmaceutical contract development and manufacturing, and hospitals and imaging centers requiring reliable diagnostic supply. Revenue is generated through managed-services contracts with quote-based, project-negotiated pricing. PharmaLogic is led by CEO Etienne Montagut, with Steve Chilinski as Executive Chairman and D. Scott Holbrook as GM and Chief Strategy Officer.
PharmaLogic Holdings firmographics
Firmographics- Name
- PharmaLogic Holdings
- Legal name
- PharmaLogic Holdings Corp.
- Website
- https://radiopharmacy.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaLogic Holdings is a privately held U.S. radiopharmaceutical CDMO/CMO operating multiple manufacturing facilities that provide CMC, production, and supply chain services for diagnostic and therapeutic radiopharmaceuticals to pharmaceutical sponsors, hospitals, and imaging centers.
- Ownership category
- akta.pro rank
PharmaLogic Holdings industry classification
Industry- Product category
- Radiopharmaceutical CDMO/CMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where PharmaLogic Holdings is headquartered
LocationHeadquarters
- HQ city
- Boca Raton
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
PharmaLogic Holdings business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain
Revenue model
- CDMO Services: Contract development and manufacturing services for radiopharmaceuticals, supporting drug development from clinical stages through commercial launch with CMC and technical capabilities
- CMO Diagnostics: Contract manufacturing organization services for diagnostic radiopharmaceuticals
- CMO Therapeutics: Contract manufacturing organization services for therapeutic radiopharmaceuticals
- Supply Chain & Radiopharmacy Services: Supply chain management and radiopharmacy services supporting distribution of time-sensitive radiopharmaceuticals
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PharmaLogic Holdings product offering
Product offeringCore offering
PharmaLogic Holdings is a Contract Development and Manufacturing Organization (CDMO/CMO) specializing in radiopharmaceuticals. It provides end-to-end CMC and technical capabilities for diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch, including just-in-time manufacturing, supply chain management, and radiopharmacy distribution to hospitals and imaging centers.
Product overview
PharmaLogic Holdings operates as a Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) specializing in radiopharmaceuticals. The company offers four core service offerings: CDMO Services providing end-to-end CMC and technical capabilities from clinical development through commercial launch; CMO Diagnostics for PET drug manufacturing; CMO Therapeutics for therapeutic radiopharmaceuticals including Actinium-225 based products; and Supply Chain & Radiopharmacy services for distribution of time-sensitive products. The company operates multiple manufacturing facilities across the United States including locations in Atlanta, Georgia, Idaho Falls, Idaho, Bronx, New York, Cincinnati, Salt Lake City, and Los Angeles. PharmaLogic supports pharmaceutical partners like Ratio Therapeutics in clinical supply and commercialization of targeted radiopharmaceuticals for cancer treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO Services Contract Development and Manufacturing Operations services delivering a suite of CMC and technical capabilities to support drug sponsors developing diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch.
- CMO Diagnostics Contract Manufacturing Operations for diagnostic radiopharmaceuticals, supporting production of PET drugs and imaging agents for diagnostic applications at hospitals and imaging centers.
- CMO Therapeutics Contract Manufacturing Operations for therapeutic radiopharmaceuticals, including Actinium-225 based targeted radiotherapeutics for cancer treatment, supporting larger-scale multi-dose batch production.
- Supply Chain & Radiopharmacy Integrated supply chain and radiopharmacy services enabling just-in-time distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across regional markets.
Quantifiable outcome
- Expanded manufacturing capacity to support larger-scale multi-dose batch production for clinical and potentially registrational trials
Companies that use PharmaLogic Holdings
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
PharmaLogic Holdings technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PharmaLogic Holdings partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ratio Therapeutics Inc.coreExpanded manufacturing partnership to support clinical development and future commercialization readiness of [Ac-225]RTX-2358, a FAP-targeted therapeutic radiopharmaceutical for cancer treatment. PharmaLogic increases manufacturing capacity at its Idaho Falls facility and implements process enhancements for larger multi-dose batch production. The collaboration supports ongoing Phase 1/2 ATLAS trial for relapsed or refractory soft tissue sarcoma and positions the program for later-stage and potentially registrational trials.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
PharmaLogic Holdings competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare offers radiopharmaceutical manufacturing and PET radiotracer products as part of its broader imaging and diagnostics portfolio. It is a large, diversified incumbent whose radiopharma business overlaps with PharmaLogic's CMO Diagnostics offering.
Direct peers
- Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with both proprietary products and contract manufacturing capabilities for diagnostic and therapeutic agents. It is a direct peer in the radiopharma CDMO/CMO space and competes for the same pharmaceutical sponsor relationships.
- Curium Pharma: Curium is one of the world's largest nuclear medicine companies, manufacturing SPECT, PET, and therapeutic radiopharmaceuticals globally. It competes head-on with PharmaLogic across both diagnostic and therapeutic CDMO/CMO services.
- Cardinal Health (Nuclear & Precision Health Solutions): Cardinal Health operates the largest radiopharmacy network in the U.S., distributing PET and SPECT agents to hospitals and imaging centers. Its nuclear pharmacy services directly overlap with PharmaLogic's Supply Chain & Radiopharmacy offering.
- Jubilant Radiopharma: Jubilant operates one of the largest commercial radiopharmaceutical manufacturing networks, supplying nuclear medicine products across the U.S. and internationally. It directly competes with PharmaLogic in radiopharmacy distribution and contract manufacturing.
- PETNET Solutions (Siemens Healthineers): PETNET operates the largest U.S. network of PET radiopharmacy manufacturing and distribution centers. It is the closest direct competitor to PharmaLogic's CDMO + radiopharmacy model, serving the same hospital and imaging-center customer base with short-half-life diagnostic radiopharmaceuticals.
- IBA Molecular (now part of Curium): IBA Molecular was a major global radiopharmaceutical manufacturer (now integrated into Curium) and competed directly with PharmaLogic in PET and SPECT agent manufacturing for hospital and clinical customers.
Emerging players
- Bracco Imaging: Bracco manufactures diagnostic imaging agents and contrast media with growing activity in radiopharmaceuticals. It is comparable to PharmaLogic as an adjacent diagnostics manufacturer expanding into nuclear medicine.
- SOFIE Biosciences (acquired by Cardinal Health): SOFIE was a theranostics-focused radiopharma manufacturer and radiopharmacy operator before being acquired by Cardinal Health. It represents the kind of emerging, specialized radiopharma manufacturer competing for the same therapeutic CDMO business PharmaLogic targets.
- Telix Pharmaceuticals: Telix develops and manufactures its own theranostic radiopharmaceuticals (e.g., Illuccix) and operates manufacturing infrastructure. It overlaps with PharmaLogic both as a potential sponsor-customer and as an emerging competitor in targeted radiotherapeutics and PSMA imaging agents.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
PharmaLogic Holdings social profiles
Digital presencePharmaLogic Holdings financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaLogic Holdings leadership team
Management profileNumber of profiles
Profiles3 records
PharmaLogic Holdings subsidiaries and ownership
Company hierarchySubsidiaries1 record
PharmaLogic Holdings funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaLogic Holdings M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaLogic Holdings
What does PharmaLogic Holdings do?
PharmaLogic Holdings is a Contract Development and Manufacturing Organization (CDMO/CMO) specializing in radiopharmaceuticals. It provides end-to-end CMC and technical capabilities for diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch, including just-in-time manufacturing, supply chain management, and radiopharmacy distribution to hospitals and imaging centers.
Is PharmaLogic Holdings a public or private company?
PharmaLogic Holdings is a private company. It is classified as unknown and is currently operating.
When was PharmaLogic Holdings founded?
PharmaLogic Holdings was founded in 1993. It employs 11 to 50 people.
Where is PharmaLogic Holdings based?
PharmaLogic Holdings is headquartered in Boca Raton, United States, in the North America region.
How does PharmaLogic Holdings make money?
Four revenue lines are on record. CDMO Services are the primary driver. The others are CMO Diagnostics, CMO Therapeutics and supply Chain & Radiopharmacy Services.
Who are PharmaLogic Holdings's main competitors?
GE HealthCare is listed as a broad incumbent. Direct peers are Lantheus Holdings, Curium Pharma, Cardinal Health (Nuclear & Precision Health Solutions), Jubilant Radiopharma, PETNET Solutions (Siemens Healthineers) and IBA Molecular (now part of Curium). Emerging players are Bracco Imaging, SOFIE Biosciences (acquired by Cardinal Health) and Telix Pharmaceuticals.
Does PharmaLogic Holdings have an API?
No public API is recorded for PharmaLogic Holdings.
What industry is PharmaLogic Holdings in?
PharmaLogic Holdings's product category is Radiopharmaceutical CDMO/CMO Services. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 325412 and its SIC code is 2834.